Vorolanib clinical trials
Also written EYP-1901.
How each study uses vorolanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the vorolanib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2018 (5)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 24 · Other 11
AnewPharma (13) · EyePoint Pharmaceuticals, Inc. (8) · Washington University School of Medicine (3) · Tyrogenex (2) · Dong Wen (1) · Vanderbilt-Ingram Cancer Center (1) · University of Wisconsin, Madison (1) · Peking University Cancer Hospital & Institute (1)
Often tested with
Tested in the same studies.
Toripalimab (4) · Cadonilimab (2) · Everolimus (1) · Sintilimab (1) · Pucotenlimab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 2 in phase 3
Studies that test vorolanib, phase 3 first.
- Oct 2027CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPhase 3 · EyePoint Pharmaceuticals, Inc.
- Oct 2027COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPhase 3 · EyePoint Pharmaceuticals, Inc.
- Dec 2026Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCCPhase 2 · Sun Yat-sen University
- Jun 2027Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic ImpairmentPhase 1 · Betta Pharmaceuticals Co., Ltd.
- Aug 2027Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsPhase 1/2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Studies
Open first, then newest update. How each study uses vorolanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 35
- Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic ImpairmentRecruitingPhase 1Betta Pharmaceuticals Co., Ltd.NCT07809802Written as vorolanib
- Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCCRecruitingPhase 2Sun Yat-sen UniversityNCT07386158Written as Pucotenlimab combination with Vorolanib
- A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKINot yet recruitingPhase 3Peking University Cancer Hospital & InstituteNCT07165418Written as Vorolanib Tablets+Everolimus
- Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06577961Written as Vorolanib
- Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination TherapyNot yet recruitingPhase 2Hao ZengNCT06523049Written as Vorolanib Tablets
- A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung CancerRecruitingPhase 2Henan Cancer HospitalNCT06406673Written as Cadonilimab+vorolanib
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Active, not recruitingPhase 3EyePoint Pharmaceuticals, Inc.NCT06683742Written as EYP-1901
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56Active, not recruitingPhase 3EyePoint Pharmaceuticals, Inc.NCT06668064Written as EYP-1901
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEActive, not recruitingPhase 3EyePoint Pharmaceuticals, Inc.NCT07449923Written as EYP-1901
- COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEActive, not recruitingPhase 3EyePoint Pharmaceuticals, Inc.NCT07449936Written as EYP-1901
- Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerTerminatedPhase 2Washington University School of MedicineNCT04373369Written as Vorolanib
- Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)CompletedPhase 2EyePoint Pharmaceuticals, Inc.NCT05381948Written as EYP-1901
- Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)CompletedPhase 2EyePoint Pharmaceuticals, Inc.NCT05383209Written as EYP-1901
- Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell CarcinomaActive, not recruitingPhase 2Dong WenNCT07047001Written as Vorolanib Tablets
- Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)CompletedPhase 2EyePoint Pharmaceuticals, Inc.NCT06099184Written as EYP-1901
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsCompletedPhase 1/2Vanderbilt-Ingram Cancer CenterNCT03583086Written as Vorolanib
- First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)CompletedPhase 1EyePoint Pharmaceuticals, Inc.NCT04747197Written as EYP-1901
- The Absorption, Metabolism and Excretion of [14C]CM082 in HumanCompletedPhase 1AnewPharmaNCT04434326Written as [14]CM082 suspension
- Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsStatus unknownPhase 1AnewPharmaNCT03792958Written as CM082
- Safety Study of X-82 in Patients With Advanced Solid TumorsCompletedPhase 1TyrogenexNCT01296581Written as X-82
Codes
What other systems call vorolanib · ClinicalTrials.gg INT001380
- MeSH (NLM) C000709220vorolanibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YP8G3I74ELVOROLANIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27294638vorolanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95896VorolanibOne source FDA
- DrugBank DB15247One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709220 | vorolanib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YP8G3I74EL | VOROLANIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27294638 | vorolanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95896 | Vorolanib | One source FDA |
| DrugBank | DB15247 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.